Better Drugs, Hep C Testing and Baby Boomers | Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search
Previous

Bavituximab to Star in Phase II Hepatitis C Trial

Back to News Homepage
Next

Telaprevir Receives Quick FDA Review

Better Drugs, Hep C Testing and Baby Boomers

The Editors at Hepatitis Central
January 24, 2011

Print this page

Two new drugs expected to enter the market soon appear to nearly double the success rate of Hepatitis C treatment. As a result of this therapeutic improvement, the age group most at risk for the Hepatitis C virus may be routinely screened for this infection.

New drugs take aim at hepatitis C, spur debate on whether to test baby boomers

By Lauran Neergaard (CP) – Jan 17, 2011

WASHINGTON — There’s new hope for an overlooked epidemic: Two powerful drugs are nearing the market that promise to help cure many more people of liver-attacking hepatitis C — even though most who have the simmering infection don’t know it yet.

Surprisingly, two-thirds of hepatitis C sufferers are thought to be baby boomers who’ve harboured since their younger, perhaps wilder, years a virus that can take two or three decades to do its damage.

What could be a treatment revolution is spurring the government to consider if it’s time to start screening aging baby boomers for hepatitis C, just like they get various cancer checks.

Continue reading this entire article:
http://www.google.com/hostednews/canadianpress/article/ALeqM5jIimWDRCH6cTQvX2W852dHURUBwA?docId=5676894

No Comments - be the first!
Share
Share
Previous

Bavituximab to Star in Phase II Hepatitis C Trial

Back to News Homepage
Next

Telaprevir Receives Quick FDA Review

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.